Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
What is your preferred front line regimen for metastatic squamous cell NSCLC that is PD-L1 and driver mutation negative?
How do you select between the available treatment options (gemcitabine, docetaxel, paclitaxel, nab-paclitaxel) in combination with platinum?
Update: KEYNOTE-407 demonstrated improved overall survival with chemo/pembrolizumab vs. chemotherapy alone. How do you now select between the various treatment options?
Answer from: Medical Oncologist at Community Practice
I believe each are acceptable options. I have generally been using carboplatin and weekly paclitaxel fairly commonly. This regimen is based on Quoix, et al Lancet trial. This study was in elderly patients. I find this very well tolerated with low chances of cytopenias, alopecia. If I have concerns a...
Sign in or Register to read more